Dynocardia is one of 10 finalist companies with optics, imaging and photonics-enabled technologies that’s working with NextCorps’ Luminate NY accelerator as part of its fourth cohort. Each company received an initial investment of $100,000 and is participating in the six-month program, which helps the selected companies speed the commercialization of their technologies and businesses. On September 30 at Finals 2021, they will compete for up to $2 million in follow-on investment. Funding for the $25 million program is being provided through the Finger Lakes Forward Upstate Revitalization Initiative.
“This year’s Luminate cohort is comprised of dedicated inventors and entrepreneurs committed to disrupting the industries they serve,” said Dr. Sujatha Ramanujan, managing director of Luminate. “The Dynocardia team is hard at work changing the face of healthcare by creating a fundamentally new way to accurately and continuously measure blood pressure (BP).”
The Rochester Business Journal is featuring profiles of the companies that are helping to write the next chapter in Rochester’s history as the world’s center for optics, photonics and imaging (OPI).
We caught up with Mohan Thanikachalam M.D., Dynocardia’s co-founder and CEO, to discuss how his company is working to improve cardiovascular health around the world.
Tell us about your company.
Dynocardia is an early-stage biomedical device development company committed to satisfying critical, unmet needs to improve cardiovascular health worldwide. Our platform technology, ViTrack™, is powered by our proprietary method to measure blood pressure, and is the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional (occlusive) devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile and easy to use, with the accuracy of intra-arterial lines. The technology also provides continuous and accurate measures of heart rate, respiratory rate and other cardio-hemodynamic parameters.
We are now laying the groundwork for entry into hospitals, the critical care sub-segment and will eventually deploy our device into a variety of care settings, including the consumer market. Over time, we will be producing crucial and unique predictive insights that will benefit the entire healthcare ecosystem.